CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 282 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
liraglutide 3.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02963935
NCT02963935Phase 3Completed
CompareCT.gov

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Novo Nordisk A/S·interventional·Posted Nov 15, 2016·Updated Mar 11, 2020

In Brief

A Phase 3 clinical trial evaluating liraglutide, placebo, and 1 other intervention for Metabolism and Nutrition Disorder and Obesity. Completed, enrolled 282 participants across 10 sites.

Detailed Summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolism and Nutrition Disorder, Obesity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 15, 2016
Enrollment StartFeb 6, 2017
Primary CompletionMay 23, 2018
Study CompletionJun 19, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago

Interventions

liraglutidedrug

Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

placebodrug

Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

CMS Intensive Behavior Therapybehavioral

Intensive Behaviour Therapy for obesity